Product Data Sheet

Product Name: Tyloxapol (Triton WR1339)
Cat. No.: GC30017

Chemical Properties

Cas. No.	25301-02-4		
SMILES	[H]OCCOC1=C(CC)C=C(C(CC(C)(C)C)(C)C)C=C1C.[6].[=].[<].[5].[8].[n].[m].[_].[=].[m].[n]		
Formula	$(C_{15}H_{21}O(C_2H_4O)m)n$	M.Wt	261.38(monomer)
Solubility	DMSO : ≥ 38 mg/mL;Water : 25 mg/mL	Storage	Store at -20°C,protect from light
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	Tyloxapol (Triton WR1339)		

Background

Tyloxapol (Triton WR1339) is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surfactant to aid liquefaction, removal of mucopurulent and bronchopulmonary secretions. It also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.

Tyloxapol is generally regarded as a safe stabilizer. In some studies, it is reported to causes cytotoxicity in epithelial and red blood cells, induces lysis of human Jurkat T-lymphoblasts and the apoptosis in RAW 264.7 murine macrophage-like cells and NIH/3T3 mouse fibroblast cells. These indications of cytotoxicity, however, do not reflect the in vivo use of Tyloxapol, since it is rarely used alone in clinical applications[3].

A single intravenous injection of tyloxapol at dose of 400mg/kg body weight shows three distinctive phases, sharp linear increment, slow linear increment and slow decrement of plasma lipids toward the basal levels[1]. The treatment of tyloxapol enhannces the pulmonary absorption of rh-insulin and increases the absorption of inhaled insulin in

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

diabetic rats. It might significantly increase the hypoglycemic effect of intratracheally administered insulin in diabetic rats but does not change the LDH activity[2].

[1] Rasouli M, et al. J Clin Diagn Res. 2016, 10(6):BF01-5. [2] Zheng J, et al. Chem Pharm Bull (Tokyo). 2010, 58(12):1612-1616. [3] Kristl J, et al. Toxicol Appl Pharmacol. 2008, 232(2):218-225.